Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma.

Next Previous
Search
Trial Profile

A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms THYRRAD

    • Most Recent Events

    • 01 Nov 2016 Results assessing the impact of hematocrit on pharmacokinetics and pharmacodynamics of everolimus in cancer patients (n=73) from THYRRAD and INPRES trials using semi-physiological pharmacokinetic model, published in the Clinical Pharmacokinetics Journal.
    • 11 Oct 2016 Results assessing effect of old age on pharmacokinetics of Everolimus in cancer patients (n=75) from THYRRAD and INPRES trials presented at the 41st European Society for Medical Oncology Congress
    • 14 May 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top